ArticleArchives of gynecology and obstetrics2025
Predictors of small-for-gestational-age infants in gestational diabetes mellitus: the impact of metformin use.
Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Gestational Diabetes Mellitus: A Need for Better Understanding and Wise Navigation.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGestational diabetes mellitus (GDM) affects 3%-25% of pregnancies worldwide, posing risks to maternal, fetal, and neonatal health. GDM is often associated with macrosomia and large-for-gestational-age (LGA) infants. However, the association between GDM and small-for-gestational-age (SGA) infants is less understood. This study aimed to identify predictors of SGA in women with GDM.
methodsThis retrospective study included GDM patients (GDMA1 and A2) admitted to the fetal-maternal unit between 2014 and 2023. The study population was divided into those who delivered an appropriate for gestational age (AGA) neonate and those who delivered an SGA neonate (defined as birthweight < 10th percentile. Women with pregestational diabetes mellitus were excluded. Obstetric and neonatal outcomes were compared between the groups. A subgroup analysis focused on GDMA2 patients, comparing maternal and neonatal outcomes and treatment regimens (insulin and metformin use).
resultsThe study included 894 GDM patients. Compared to the AGA group (n = 712), the SGA group (n = 182) had lower maternal BMI (p = 0.02). Maternal age was comparable between groups. Rates of GDMA2 (30.2% vs. 23.4%, p = 0.07), and hypertensive disorders (7.1% vs. 5%, p = 0.21) did not differ significantly between the groups. The neonatal birthweight of the SGA infants was 2375 ± 432 g vs. 3021 ± 165 g in the AGA infants, (p = 0.005). The SGA group had a higher rate of CD due to NRFHR (27.4% vs. 18.4%, p < 0.01). Among GDMA2 patients (n = 222), more women in the SGA group (n = 55) were treated with metformin as compared to the AGA group (n = 167) (72.7% vs. 23.9%, p < 0.001). Multivariate regression analysis revealed that among GDMA2 patients metformin treatment was independently associated with SGA neonates OR 1.7, CI 1.18-1.35, p < 0.01).
conclusionMetformin use in GDMA2 pregnancies may be linked to SGA neonates. The impact of metformin on fetal growth highlights the need for careful monitoring and individualized treatment strategies in managing GDMA2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.